Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Dermira Inc (DERM)

Dermira Inc (DERM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 309,525
  • Shares Outstanding, K 54,398
  • Annual Sales, $ 42,340 K
  • Annual Income, $ -221,540 K
  • 60-Month Beta 1.32
  • Price/Sales 7.04
  • Price/Cash Flow N/A
  • Price/Book 4.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -1.40
  • Number of Estimates 3
  • High Estimate -1.28
  • Low Estimate -1.48
  • Prior Year -1.58
  • Growth Rate Est. (year over year) +11.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.30 +7.42%
on 10/10/19
9.14 -37.75%
on 09/12/19
-3.36 (-37.13%)
since 09/11/19
3-Month
5.30 +7.42%
on 10/10/19
9.48 -39.98%
on 09/11/19
-3.12 (-35.41%)
since 07/11/19
52-Week
5.30 +7.42%
on 10/10/19
15.48 -63.24%
on 04/08/19
-5.45 (-48.92%)
since 10/11/18

Most Recent Stories

More News
Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study

Dermira (DERM) starts a phase III program for evaluation of its monoclonal antibody candidate, lebrikizumab, in adolescents and adult patients with atopic dermatitis, the most common form of eczema.

LLY : 108.36 (+1.35%)
SNY : 44.95 (+0.25%)
REGN : 300.77 (+0.81%)
DERM : 5.69 (+3.83%)
Dermira to Present Data from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis at Fall Clinical Dermatology Conference

Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with...

DERM : 5.69 (+3.83%)
Look for Shares of Dermira to Potentially Rebound after Yesterday's 1.40% Sell Off

Dermira (NASDAQ:DERM) traded in a range yesterday that spanned from a low of $5.61 to a high of $5.88. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $5.63 on volume...

DERM : 5.69 (+3.83%)
Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis

--- Topline results from the 16-week induction period expected in the first half of 2021

DERM : 5.69 (+3.83%)
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with...

DERM : 5.69 (+3.83%)
Lannett Co Inc is Among the Companies in the Pharmaceuticals Industry with the Best Relative Performance (LCI , PCRX , DERM , BMY , HZNP )

Here are the top 5 stocks in the Pharmaceuticals industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

DERM : 5.69 (+3.83%)
LCI : 11.06 (-0.27%)
PCRX : 37.69 (+2.50%)
Dermira Shares Down 44.8% Since SmarTrend's Sell Call (DERM)

SmarTrend identified a Downtrend for Dermira (NASDAQ:DERM) on May 2nd, 2019 at $10.44. In approximately 5 months, Dermira has returned 44.83% as of today's recent price of $5.76.

DERM : 5.69 (+3.83%)
Intra-Cellular T has the Best Relative Performance in the Pharmaceuticals Industry (ITCI , LCI , DERM , JNJ , MDCO )

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...

DERM : 5.69 (+3.83%)
ITCI : 7.76 (-2.21%)
LCI : 11.06 (-0.27%)
Dermira to Participate in the 2019 Cantor Global Healthcare Conference

Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with...

DERM : 5.69 (+3.83%)
Look for Shares of Dermira to Potentially Rebound after Yesterday's 5.04% Sell Off

Dermira (NASDAQ:DERM) traded in a range yesterday that spanned from a low of $7.15 to a high of $7.60. Yesterday, the shares fell 5.0%, which took the trading range below the 3-day low of $7.51 on volume...

DERM : 5.69 (+3.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade DERM with:

Business Summary

Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage...

See More

Key Turning Points

2nd Resistance Point 5.86
1st Resistance Point 5.78
Last Price 5.69
1st Support Level 5.59
2nd Support Level 5.48

See More

52-Week High 15.48
Fibonacci 61.8% 11.59
Fibonacci 50% 10.39
Fibonacci 38.2% 9.19
Last Price 5.69
52-Week Low 5.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar